Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2019

Aug 09, 2019

SELL
$6.0 - $9.0 $630,000 - $945,000
-105,000 Closed
0 $0
Q1 2019

May 10, 2019

BUY
$7.14 - $9.85 $749,700 - $1.03 Million
105,000 New
105,000 $948,000

Others Institutions Holding ALDX

About Aldeyra Therapeutics, Inc.


  • Ticker ALDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,323,100
  • Market Cap $280M
  • Description
  • Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...
More about ALDX
Track This Portfolio

Track Prescott Group Capital Management, L.L.C. Portfolio

Follow Prescott Group Capital Management, L.L.C. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Prescott Group Capital Management, L.L.C., based on Form 13F filings with the SEC.

News

Stay updated on Prescott Group Capital Management, L.L.C. with notifications on news.